Oxford Biodynamics will release FY results on 24th Jan. at 2pm.
Jon Burrows, CEO presents these results and updates on current performance in a webinar for investors.
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
Register here
